ArticleJournal of inflammation research2025
Protective Effect of Hordenine on Concanavalin A-Induced Hepatic Injury.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the protective effects of hordenine on concanavalin A (ConA)-induced immune liver injury (ILI). Methods: Liver coefficients and spleen coefficients were determined. The serum levels of alanine transaminase (ALT) and aspartate transaminase (AST) were detected. Hematoxylin-eosin (H&E) staining was used to observe the pathological changes of the liver, spleen, and thymus. Immunohistochemical experiments were performed to detect the expression of inflammatory factors interleukin (IL)-6, IL-1β, and tumor necrosis factor alpha (TNF-α) in liver tissues. Superoxide dismutase (SOD) and malondialdehyde (MDA) contents were detected. TdT-Mediated dUTP Nick-End Labeling (TUNEL) staining was used to observe the apoptosis of liver cells. Western Blot was used to detect the expression of B-cell lymphoma-2 (Bcl-2), Caspase-3, Bcl-2-Associated X (Bax), kelch-like ECH-associated protein 1 (Keap1), nuclear factor erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1). Results: We found that hordenine alleviated liver and spleen enlargement, ameliorated pathological damage in the liver, spleen, and thymus, and reduced transaminase and inflammatory factor levels in the liver. Moreover, hordenine increased the level of SOD while decreasing the level of MDA, attenuated hepatic apoptosis, decreased the expression of caspase-3, Bax, and Keap1 and increased the expression of Bcl-2, Nrf2, and HO-1. Conclusion: These results suggest that hordenine has a protective effect against ConA-induced immune liver injury, which may be related to its modulation of the Keap1/Nrf2/HO-1 pathway and inhibition of oxidative stress and apoptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.